Dr. Lang focuses on mechanisms of therapeutic resistance in prostate cancer, with an extensive track record in research, education, and service. He is a first-generation college graduate who, after completing graduate school at the University of Illinois, pursued medical training and cancer research. He completed the PSTP at the University of Wisconsin and began a tenure-track position in 2012, with promotion to Associate Professor in 2017 and Professor in 2024.

His research spans molecular biology and translational research through the development of liquid biopsies and targeted therapies.  He patented technologies for genomic, transcriptomic and single cell phenotyping of liquid biopsies. These assays have been integrated in over twenty clinical trials. He has over 90 publications, including Cancer Discovery, JCI, and JCO. His collaborative nature has led to successful funding as PI on multiple R01s and P01.

Dr. Lang's has a demonstrated commitment to service with involvement in multiple societies, including ASCO, AACR, and NCCN. He has been a voting member of the NCCN prostate cancer committee since 2016 and joined the US Prostate Cancer Consensus Committee.  He serves as a peer reviewer for numerous journals, including JCI, Cancer Discovery and many others. He is a standing member of the NCI CONC study section.

Dr. Lang also holds leadership roles as the Associate Director of Translational Research at the UW Carbone Cancer Center, co-Director for the UW Physician Scientist Training Program. His leadership significantly enhanced the training and research programs of biomedical researchers, fostering an environment of innovation and excellence.  His efforts have been recognized with multiple accolades, including induction into Alpha Omega Alpha Honor Society, the UW Vilas Distinguished Achievement Professorship and the Department of Medicine Mentorship Award. He has mentored over 25 graduate students, post-doctoral trainees, and fellows and seven now hold faculty positions.